Sermorelin and ipamorelin are both synthetic peptides designed to stimulate the natural release of growth hormone from the pituitary gland, but they differ in structure, potency, duration of action, side-effect profile, and clinical applications. Tesamorelin is another growth-hormone-releasing factor (GHRF) that shares similarities with sermorelin yet has distinct indications and pharmacokinetics.

Comparing the Benefits of Sermorelin vs Ipamorelin vs Tesamorelin

Sermorelin

Mechanism: Mimics growth hormone-releasing hormone (GHRH), binding to its receptor on pituitary somatotrophs.

Clinical Use: Primarily used for diagnosing growth hormone deficiency in adults and children, and occasionally as a therapeutic agent to increase GH levels in deficient patients.

Benefits: Produces a physiological pattern of GH release with minimal suppression of other pituitary hormones. The dose is relatively low (usually 0.2–0.5 mg/day), reducing cost and potential for adverse effects.

Ipamorelin

Mechanism: Acts as a selective ghrelin receptor agonist, stimulating GH secretion without significant prolactin or ACTH release.

Clinical Use: Often used off-label for anti-aging, muscle growth, fat loss, and recovery in athletes

Edit

Pub: 09 Oct 2025 09:48 UTC

Views: 17